出版：MarketsandMarkets（マーケッツアンドマーケッツ） 出版年月：2024年4月
Allergy Diagnostics Market – Global Forecast To 2029
アレルギー診断市場 : 製品とサービス [消耗品、機器 (免疫測定分析装置、照度計)、サービス]、検査タイプ [生体内 (皮膚穿刺、パッチ)、体外]、アレルゲン (食品、吸入性、薬剤)、エンドユーザー、地域別 – 2029年までの世界予測
Allergy Diagnostics Market by Product & Service (Consumables, Instruments (Immunoassay Analyzer, Luminometer), Services), Test Type (In Vivo (Skin Prick, Patch), In Vitro), Allergen (Food, Inhaled, Drug), End User, & Region – Global Forecast to 2029
| ページ数 | 294 |
| 図表数 | 405 |
| 価格 | |
| シングルユーザライセンス | USD 4,950 |
| マルチユーザライセンス（5名） | USD 6,650 |
| コーポレートライセンス | USD 8,150 |
| エンタープライズサイトライセンス | USD 10,000 |
| 種別 | 英文調査報告書 |
Report Overview
The global Allergy Diagnostics market is projected to reach USD 9.8 billion by 2029 from USD 5.3 billion in 2024, at a CAGR of 11.0% during the forecast period.
世界のアレルギー診断市場は、予測期間中のCAGR 11.0%で、2024年の53億米ドルから2029年までに98億米ドルに達すると予測されています。
The growth of this market is majorly driven by rise in awareness program by government and associations, growing allergy research, and rise in innovative technologies for allergy diagnosis. However, a smaller number of allergists and poor implementation of allergy testing methods could restrain the growth of the Allergy Diagnostics market.
“Consumables segment accounted for the highest market share in the Allergy Diagnostics market, by product & service, during the forecast period.”
Based on product & service, the Allergy Diagnostics market is segmented into consumables, instruments, and services. In 2023, the consumables segment accounted for the largest share of the Allergy Diagnostics market. Growing prevalence of allergies including inhaled and food allergies and emergence of local players in in vivo test kits to drive the market of this segment during the forecast period. This segment is also anticipated to witness substantial growth over the projected period.
“In Vivo type of tests accounted for the larger market share in the Allergy Diagnostics market, by test type, during the forecast period.”
The Allergy Diagnostics market is segmented into in vivo tests and in vitro tests based on test type. The in vivo tests segment accounted for the largest share of the Allergy Diagnostics market in 2023 and is also projected to acquire highest CAGR during the forecast period. The growth of in vivo test segment is majorly driven by the increase in demand for point-of care testing and growing awareness about allergic symptoms and need for getting tested.
“Hospital-based laboratories & clinics accounted for the highest CAGR during the forecast period.”
Based on the end user, the Allergy Diagnostics market is segmented into diagnostic laboratories, hospital-based laboratories & clinics, academic research institutes, and other end users. In 2023, the hospital-based laboratories & clinics segment accounted for the largest share of the market. The clinics’ significant end-user standing for in vivo allergy testing and their convenience in terms of allergy management and treatment options are the main reasons for their substantial market share.
“The North America segment accounted for the highest market share in the Allergy Diagnostics market, by region, during the forecast period.”
Based on the region, the Allergy Diagnostics market is divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. North America region accounted for the largest share of the global Allergy Diagnostics market in 2023. This large share of North America is due to the growing incidence of food and respiratory allergies, rise in agreement for awareness between government and associations, and presence of major players in the region.
Breakdown of supply-side primary interviews by company type, designation, and region:
- By Company Type: Tier 1 (20%), Tier 2 (45%), and Tier 3 (35%)
- By Designation: C-level (30%), Director-level (20%), and Others (50%)
- By Region: North America (36%), Asia- Pacific (27%), Europe (25%), and Latin America- (7%) and MEA-(5%)
Prominent companies include Thermo Fisher Scientific Inc., (US), Siemens Healthineers Ag (Germany), Danaher Corporation (US), Minaris Medical America, Inc. (US), Omega Diagnostics Group PLC (UK), bioMérieux SA (France), Romer Labs Division Holding (Austria), EUROIMMUN Medizinische Labordiagnostika AG (Germany), HollisterStier Allergy (US), Eurofins Scientific (Luxembourg), and Stallergenes Greer (UK).
Research Coverage
This research report categorizes the Allergy Diagnostics market by product & service, test type, allergen, end user, and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the Allergy Diagnostics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, services; key strategies; Contracts, partnerships, and agreements. New product launches, mergers and acquisitions, and recent developments associated with the Allergy Diagnostics market. Competitive analysis of upcoming startups in the Allergy Diagnostics market ecosystem is covered in this report.
Key Benefits of Buying the Report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall Allergy Diagnostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
• Analysis of key drivers (global rise in prevalence and heavy economic burden of allergic illnesses, growing environmental pollution, and insurance coverage), restraints (high costs of analyzers and access is limited to healthcare services), opportunities (use of mHealth and integration of AI in allergy diagnosis), and challenges (a few number of allergists and challenges during diagnosis of allergy) influencing the growth of the Allergy Diagnostics market
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the Allergy Diagnostics market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the Allergy Diagnostics market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Allergy Diagnostics market
• Competitive Assessment: In-depth assessment of market ranking, growth strategies, and service offerings of leading players like Thermo Fisher Scientific Inc., (US), Siemens Healthineers AG (Germany), Danaher (US), and Canon, Inc. (Japan) [Minaris Medical America, Inc. (US)], among others in the Allergy Diagnostics market strategies.
Table of Contents
1 INTRODUCTION 43
1.1 STUDY OBJECTIVES 43
1.2 MARKET DEFINITION 43
1.3 INCLUSIONS AND EXCLUSIONS 44
1.4 MARKET SEGMENTATION 44
1.4.1 MARKETS COVERED 44
1.4.2 REGIONS COVERED 45
1.4.3 YEARS CONSIDERED 45
1.4.4 CURRENCY CONSIDERED 46
1.5 MARKET STAKEHOLDERS 46
1.6 SUMMARY OF CHANGES 46
1.7 RECESSION IMPACT 47
2 RESEARCH METHODOLOGY 48
2.1 RESEARCH DATA 48
FIGURE 1 ALLERGY DIAGNOSTICS MARKET: RESEARCH DESIGN METHODOLOGY 48
2.1.1 SECONDARY DATA 48
2.1.1.1 Secondary sources 50
2.1.2 PRIMARY DATA 50
TABLE 1 KEY DATA FROM PRIMARY SOURCES 51
FIGURE 2 KEY INDUSTRY INSIGHTS 52
2.1.2.1 Breakdown of primary interviews 52
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 52
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 53
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY END USER, DESIGNATION, AND REGION 53
2.1.3 MARKET SIZE ESTIMATION 54
FIGURE 6 BOTTOM-UP APPROACH: REVENUE-BASED APPROACH 54
2.1.3.1 Growth forecast 55
2.1.3.2 CAGR projections 55
FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 55
2.1.4 TOP-DOWN APPROACH 56
FIGURE 8 ALLERGY DIAGNOSTICS MARKET: TOP-DOWN APPROACH 56
2.2 MARKET BREAKDOWN AND DATA TRIANGULATION 57
FIGURE 9 DATA TRIANGULATION METHODOLOGY 57
2.3 STUDY ASSUMPTIONS 58
TABLE 2 ALLERGY DIAGNOSTICS MARKET: IMPACT ANALYSIS 58
2.4 RISK ASSESSMENT 58
TABLE 3 ALLERGY DIAGNOSTICS MARKET: RISK ASSESSMENT ANALYSIS 58
2.5 RESEARCH LIMITATIONS 58
2.6 RECESSION IMPACT ANALYSIS 59
3 EXECUTIVE SUMMARY 60
FIGURE 10 ALLERGY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024 VS. 2029 (USD BILLION) 60
FIGURE 11 ALLERGY DIAGNOSTICS MARKET, BY TEST TYPE, 2024 VS. 2029 (USD BILLION) 61
FIGURE 12 ALLERGY DIAGNOSTICS MARKET, BY ALLERGEN, 2024 VS. 2029 (USD BILLION) 61
FIGURE 13 ALLERGY DIAGNOSTICS MARKET, BY END USER, 2024 VS. 2029 (USD BILLION) 62
FIGURE 14 REGIONAL SNAPSHOT OF ALLERGY DIAGNOSTICS MARKET 63
4 PREMIUM INSIGHTS 64
4.1 ALLERGY DIAGNOSTICS MARKET OVERVIEW 64
FIGURE 15 INCREASING NUMBER OF GOVERNMENT INITIATIVES AND INVESTMENTS TO DRIVE MARKET 64
4.2 ASIA PACIFIC: ALLERGY DIAGNOSTICS MARKET, BY ALLERGEN AND COUNTRY (2023) 65
FIGURE 16 CHINA AND INHALED ALLERGENS ACCOUNTED FOR LARGEST MARKET SHARE IN 2023 65
4.3 ALLERGY DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 66
FIGURE 17 CHINA TO REGISTER HIGHEST GROWTH RATE DURING STUDY PERIOD 66
4.4 ALLERGY DIAGNOSTICS MARKET: REGIONAL MIX 66
FIGURE 18 ASIA PACIFIC TO WITNESS FASTEST GROWTH DURING FORECAST PERIOD 66
4.5 ALLERGY DIAGNOSTICS MARKET: DEVELOPED VS. EMERGING ECONOMIES 67
FIGURE 19 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD 67
5 MARKET OVERVIEW 68
5.1 INTRODUCTION 68
5.2 MARKET DYNAMICS 68
FIGURE 20 ALLERGY DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 68
5.2.1 DRIVERS 69
5.2.1.1 High incidence and heavy economic burden of allergic diseases 69
5.2.1.2 Increasing awareness about allergies 69
5.2.1.3 Rising environmental pollution levels 70
5.2.1.4 Increased funding for allergy diagnostics 71
5.2.1.5 Coverage of allergy diagnosis under health insurance schemes 71
5.2.2 RESTRAINTS 72
5.2.2.1 Premium cost of allergy diagnostic instruments 72
5.2.2.2 Lack of adequate knowledge and poor implementation of allergy testing methods 72
5.2.2.3 Limited access to healthcare services 72
5.2.3 OPPORTUNITIES 73
5.2.3.1 Use of mHealth in allergy diagnosis 73
5.2.3.2 Integration of artificial intelligence in allergy diagnosis 73
5.2.4 CHALLENGES 74
5.2.4.1 Shortage of allergists and lack of training programs 74
5.2.4.2 Diagnostic challenges in allergic patients 74
5.2.5 TRENDS 75
5.2.5.1 Rising use of reagent rental agreements and cost-per-test contracts 75
5.2.5.2 Increasing use of molecular diagnostics and point-of-care allergy testing 75
5.3 PRICING ANALYSIS 76
TABLE 4 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT 76
TABLE 5 AVERAGE SELLING PRICE TREND, BY REGION 76
5.4 PATENT ANALYSIS 77
FIGURE 21 PATENT ANALYSIS FOR ALLERGY DIAGNOSTIC PRODUCTS (JANUARY 2014–DECEMBER 2023) 77
5.5 VALUE CHAIN ANALYSIS 78
FIGURE 22 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES 78
5.6 SUPPLY CHAIN ANALYSIS 79
FIGURE 23 ALLERGY DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS 79
5.7 ECOSYSTEM ANALYSIS 80
FIGURE 24 ALLERGY DIAGNOSTICS MARKET: ECOSYSTEM/MARKET MAP 80
5.7.1 ALLERGY DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM 80
FIGURE 25 KEY PLAYERS IN ALLERGY DIAGNOSTICS MARKET 81
5.8 PORTER’S FIVE FORCES ANALYSIS 81
TABLE 6 ALLERGY DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 81
5.8.1 DEGREE OF COMPETITION 82
5.8.2 BARGAINING POWER OF SUPPLIERS 82
5.8.3 BARGAINING POWER OF BUYERS 82
5.8.4 THREAT OF SUBSTITUTES 82
5.8.5 THREAT OF NEW ENTRANTS 82
5.9 REGULATORY ANALYSIS 83
5.9.1 REGULATORY LANDSCAPE 83
5.9.1.1 North America 83
5.9.1.1.1 US 83
TABLE 7 US: CLASSIFICATION OF IMMUNOASSAY PRODUCTS 83
FIGURE 26 US: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 84
5.9.1.1.2 Canada 85
FIGURE 27 CANADA: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 85
5.9.1.2 Europe 85
TABLE 8 EUROPE: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES 85
FIGURE 28 EUROPE: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 86
5.9.1.2.1 Russia 87
TABLE 9 RUSSIA: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES 87
5.9.1.3 Asia Pacific 88
5.9.1.3.1 Japan 88
FIGURE 29 JAPAN: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 88
TABLE 10 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 88
5.9.1.3.2 China 89
TABLE 11 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 89
5.9.1.3.3 India 89
FIGURE 30 INDIA: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 90
5.9.1.3.4 Indonesia 90
TABLE 12 INDONESIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 91
5.9.1.3.5 South Korea 91
TABLE 13 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 91
5.9.1.4 Middle East & Africa 91
5.9.1.4.1 Saudi Arabia 91
TABLE 14 SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 92
5.9.1.5 Latin America 92
5.9.1.5.1 Mexico 92
FIGURE 31 MEXICO: REGULATORY PROCESS FOR IN-VIRTO DIAGNOSTIC DEVICES 92
TABLE 15 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 93
5.9.1.5.2 Brazil 93
FIGURE 32 BRAZIL: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 94
5.9.2 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 94
TABLE 16 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 94
TABLE 17 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 95
TABLE 18 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 95
TABLE 19 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 96
5.10 TRADE ANALYSIS 96
5.10.1 EXPORT DATA FOR HS CODE 902750 96
TABLE 20 EXPORT DATA FOR HS CODE 902750, BY COUNTRY, 2019–2023 (USD MILLION) 96
5.10.2 IMPORT DATA FOR HS CODE 902750 96
TABLE 21 IMPORT DATA FOR HS CODE 902750, BY COUNTRY, 2019–2023 (USD MILLION) 96
5.11 TECHNOLOGY ANALYSIS 97
5.11.1 ALLERGY DIAGNOSTICS MARKET: KEY TECHNOLOGIES 97
TABLE 22 KEY TECHNOLOGIES IN ALLERGY DIAGNOSTICS MARKET 97
5.11.2 ALLERGY DIAGNOSTICS MARKET: COMPLEMENTARY TECHNOLOGIES 97
5.12 KEY CONFERENCES AND EVENTS, 2024−2025 98
TABLE 23 ALLERGY DIAGNOSTICS MARKET: DETAILED LIST OF KEY CONFERENCES & EVENTS, JANUARY 2024–DECEMBER 2025 98
5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 99
FIGURE 33 REVENUE SHIFT IN ALLERGY DIAGNOSTICS 99
5.14 KEY STAKEHOLDERS & BUYING CRITERIA 100
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 100
FIGURE 34 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS OF ALLERGY DIAGNOSTIC PRODUCTS 100
TABLE 24 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS OF ALLERGY DIAGNOSTIC PRODUCTS 100
5.14.2 KEY BUYING CRITERIA 101
FIGURE 35 KEY BUYING CRITERIA FOR ALLERGY DIAGNOSTIC PRODUCTS 101
TABLE 25 KEY BUYING CRITERIA FOR ALLERGY DIAGNOSTIC PRODUCTS 101
6 ALLERGY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE 102
6.1 INTRODUCTION 103
TABLE 26 ALLERGY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 103
6.2 CONSUMABLES 103
6.2.1 RECURRENT USE TO DRIVE MARKET 103
TABLE 27 ALLERGY DIAGNOSTIC CONSUMABLES MARKET, BY REGION, 2022–2029 (USD MILLION) 104
TABLE 28 NORTH AMERICA: ALLERGY DIAGNOSTIC CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 104
TABLE 29 EUROPE: ALLERGY DIAGNOSTIC CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 105
TABLE 30 ASIA PACIFIC: ALLERGY DIAGNOSTIC CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 105
TABLE 31 LATIN AMERICA: ALLERGY DIAGNOSTIC CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 106
TABLE 32 MIDDLE EAST & AFRICA: ALLERGY DIAGNOSTIC CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 106
6.3 INSTRUMENTS 106
TABLE 33 ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 107
TABLE 34 ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY REGION, 2022–2029 (USD MILLION) 107
TABLE 35 NORTH AMERICA: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 107
TABLE 36 EUROPE: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 108
TABLE 37 ASIA PACIFIC: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 108
TABLE 38 LATIN AMERICA: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 109
TABLE 39 MIDDLE EAST & AFRICA: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 109
6.3.1 IMMUNOASSAY ANALYZERS 109
6.3.1.1 High preference for testing to boost demand 109
TABLE 40 IMMUNOASSAY ANALYZERS MARKET, BY REGION, 2022–2029 (USD MILLION) 110
TABLE 41 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 111
TABLE 42 EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 111
TABLE 43 ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 111
TABLE 44 LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 112
TABLE 45 MIDDLE EAST & AFRICA: IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 112
6.3.2 LUMINOMETERS 112
6.3.2.1 Convenience and ease of use to drive market 112
TABLE 46 LUMINOMETERS MARKET, BY REGION, 2022–2029 (USD MILLION) 113
TABLE 47 NORTH AMERICA: LUMINOMETERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 113
TABLE 48 EUROPE: LUMINOMETERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 114
TABLE 49 ASIA PACIFIC: LUMINOMETERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 114
TABLE 50 LATIN AMERICA: LUMINOMETERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 114
TABLE 51 MIDDLE EAST & AFRICA: LUMINOMETERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 115
6.3.3 OTHER INSTRUMENTS 115
TABLE 52 ALLERGY DIAGNOSTICS MARKET FOR OTHER INSTRUMENTS, BY REGION, 2022–2029 (USD MILLION) 116
TABLE 53 NORTH AMERICA: ALLERGY DIAGNOSTICS MARKET FOR OTHER INSTRUMENTS, BY COUNTRY, 2022–2029 (USD MILLION) 116
TABLE 54 EUROPE: ALLERGY DIAGNOSTICS MARKET FOR OTHER INSTRUMENTS, BY COUNTRY, 2022–2029 (USD MILLION) 117
TABLE 55 ASIA PACIFIC: ALLERGY DIAGNOSTICS MARKET FOR OTHER INSTRUMENTS, BY COUNTRY, 2022–2029 (USD MILLION) 117
TABLE 56 LATIN AMERICA: ALLERGY DIAGNOSTICS MARKET FOR OTHER INSTRUMENTS, BY COUNTRY, 2022–2029 (USD MILLION) 118
TABLE 57 MIDDLE EAST & AFRICA: ALLERGY DIAGNOSTICS MARKET FOR OTHER INSTRUMENTS, BY COUNTRY, 2022–2029 (USD MILLION) 118
6.4 SERVICES 118
6.4.1 RISING NEED TO ENSURE EFFECTIVE UTILIZATION OF ALLERGY DIAGNOSTIC PRODUCTS TO SUPPORT MARKET GROWTH 118
TABLE 58 ALLERGY DIAGNOSTIC SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION) 119
TABLE 59 NORTH AMERICA: ALLERGY DIAGNOSTIC SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 119
TABLE 60 EUROPE: ALLERGY DIAGNOSTIC SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 119
TABLE 61 ASIA PACIFIC: ALLERGY DIAGNOSTIC SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 120
TABLE 62 LATIN AMERICA: ALLERGY DIAGNOSTIC SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 120
TABLE 63 MIDDLE EAST & AFRICA: ALLERGY DIAGNOSTIC SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 120
7 ALLERGY DIAGNOSTICS MARKET, BY TEST TYPE 121
7.1 INTRODUCTION 122
TABLE 64 ADVANTAGES AND LIMITATIONS OF ALLERGY TESTS 122
TABLE 65 ALLERGY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 122
7.2 IN VIVO TESTS 123
TABLE 66 ALLERGY DIAGNOSTICS MARKET FOR IN VIVO TESTS, BY TYPE, 2022–2029 (USD MILLION) 123
TABLE 67 ALLERGY DIAGNOSTICS MARKET FOR IN VIVO TESTS, BY REGION, 2022–2029 (USD MILLION) 123
TABLE 68 NORTH AMERICA: ALLERGY DIAGNOSTICS MARKET FOR IN VIVO TESTS, BY COUNTRY, 2022–2029 (USD MILLION) 124
TABLE 69 EUROPE: ALLERGY DIAGNOSTICS MARKET FOR IN VIVO TESTS, BY COUNTRY, 2022–2029 (USD MILLION) 124
TABLE 70 ASIA PACIFIC: ALLERGY DIAGNOSTICS MARKET FOR IN VIVO TESTS, BY COUNTRY, 2022–2029 (USD MILLION) 125
TABLE 71 LATIN AMERICA: ALLERGY DIAGNOSTICS MARKET FOR IN VIVO TESTS, BY COUNTRY, 2022–2029 (USD MILLION) 125
TABLE 72 MIDDLE EAST & AFRICA: ALLERGY DIAGNOSTICS MARKET FOR IN VIVO TESTS, BY COUNTRY, 2022–2029 (USD MILLION) 125
7.2.1 SKIN PRICK TESTS 126
7.2.1.1 Most widely preferred in vivo allergy tests 126
TABLE 73 SKIN PRICK TESTS MARKET, BY REGION, 2022–2029 (USD MILLION) 126
TABLE 74 NORTH AMERICA: SKIN PRICK TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 126
TABLE 75 EUROPE: SKIN PRICK TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 127
TABLE 76 ASIA PACIFIC: SKIN PRICK TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 127
TABLE 77 LATIN AMERICA: SKIN PRICK TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 127
TABLE 78 MIDDLE EAST & AFRICA: SKIN PRICK TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 128
7.2.2 PATCH TESTS 128
7.2.2.1 Rapid diagnosis of contact dermatitis to boost demand 128
TABLE 79 PATCH TESTS MARKET, BY REGION, 2022–2029 (USD MILLION) 129
TABLE 80 NORTH AMERICA: PATCH TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 129
TABLE 81 EUROPE: PATCH TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 129
TABLE 82 ASIA PACIFIC: PATCH TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 130
TABLE 83 LATIN AMERICA: PATCH TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 130
TABLE 84 MIDDLE EAST & AFRICA: PATCH TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 130
7.2.3 OTHER IN VIVO TESTS 131
TABLE 85 OTHER IN VIVO TESTS MARKET, BY REGION, 2022–2029 (USD MILLION) 131
TABLE 86 NORTH AMERICA: OTHER IN VIVO TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 132
TABLE 87 EUROPE: OTHER IN VIVO TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 132
TABLE 88 ASIA PACIFIC: OTHER IN VIVO TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 132
TABLE 89 LATIN AMERICA: OTHER IN VIVO TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 133
TABLE 90 MIDDLE EAST & AFRICA: OTHER IN VIVO TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 133
7.3 IN VITRO TESTS 133
7.3.1 ABILITY TO IDENTIFY ALLERGEN-SPECIFIC IGE MOLECULES IN A PATIENT’S SERUM TO DRIVE MARKET 133
TABLE 91 ALLERGY DIAGNOSTICS MARKET FOR IN VITRO TESTS, BY REGION, 2022–2029 (USD MILLION) 134
TABLE 92 NORTH AMERICA: ALLERGY DIAGNOSTICS MARKET FOR IN VITRO TESTS, BY COUNTRY, 2022–2029 (USD MILLION) 134
TABLE 93 EUROPE: ALLERGY DIAGNOSTICS MARKET FOR IN VITRO TESTS, BY COUNTRY, 2022–2029 (USD MILLION) 135
TABLE 94 ASIA PACIFIC: ALLERGY DIAGNOSTICS MARKET FOR IN VITRO TESTS, BY COUNTRY, 2022–2029 (USD MILLION) 135
TABLE 95 LATIN AMERICA: ALLERGY DIAGNOSTICS MARKET FOR IN VITRO TESTS, BY COUNTRY, 2022–2029 (USD MILLION) 136
TABLE 96 MIDDLE EAST & AFRICA: ALLERGY DIAGNOSTICS MARKET FOR IN VITRO TESTS, BY COUNTRY, 2022–2029 (USD MILLION) 136
8 ALLERGY DIAGNOSTICS MARKET, BY ALLERGEN 137
8.1 INTRODUCTION 138
TABLE 97 ALLERGY DIAGNOSTICS MARKET, BY ALLERGEN, 2022–2029 (USD MILLION) 138
8.2 INHALED ALLERGENS 138
8.2.1 HIGH INCIDENCE OF ASTHMA TO PROPEL MARKET 138
TABLE 98 INHALED ALLERGEN DIAGNOSTICS MARKET, BY REGION, 2022–2029 (USD MILLION) 139
TABLE 99 NORTH AMERICA: INHALED ALLERGEN DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 139
TABLE 100 EUROPE: INHALED ALLERGEN DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 140
TABLE 101 ASIA PACIFIC: INHALED ALLERGEN DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 140
TABLE 102 LATIN AMERICA: INHALED ALLERGEN DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 141
TABLE 103 MIDDLE EAST & AFRICA: INHALED ALLERGEN DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 141
8.3 FOOD ALLERGENS 141
8.3.1 HIGH PREVALENCE AMONG CHILDREN TO SUPPORT MARKET GROWTH 141
TABLE 104 SPECIFIC FOOD-INDUCED ALLERGIC CONDITIONS 142
TABLE 105 FOOD ALLERGEN DIAGNOSTICS MARKET, BY REGION, 2022–2029 (USD MILLION) 142
TABLE 106 NORTH AMERICA: FOOD ALLERGEN DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 143
TABLE 107 EUROPE: FOOD ALLERGEN DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 143
TABLE 108 ASIA PACIFIC: FOOD ALLERGEN DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 144
TABLE 109 LATIN AMERICA: FOOD ALLERGEN DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 144
TABLE 110 MIDDLE EAST & AFRICA: FOOD ALLERGEN DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 144
8.4 DRUG ALLERGENS 145
8.4.1 INCREASING INCIDENCE OF DRUG ALLERGIES TO DRIVE MARKET 145
TABLE 111 DRUG ALLERGEN DIAGNOSTICS MARKET, BY REGION, 2022–2029 (USD MILLION) 145
TABLE 112 NORTH AMERICA: DRUG ALLERGEN DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 146
TABLE 113 EUROPE: DRUG ALLERGEN DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 146
TABLE 114 ASIA PACIFIC: DRUG ALLERGEN DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 147
TABLE 115 LATIN AMERICA: DRUG ALLERGEN DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 147
TABLE 116 MIDDLE EAST & AFRICA: DRUG ALLERGEN DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 147
8.5 OTHER ALLERGENS 148
TABLE 117 OTHER ALLERGEN DIAGNOSTICS MARKET, BY REGION, 2022–2029 (USD MILLION) 148
TABLE 118 NORTH AMERICA: OTHER ALLERGEN DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 148
TABLE 119 EUROPE: OTHER ALLERGEN DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 149
TABLE 120 ASIA PACIFIC: OTHER ALLERGEN DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 149
TABLE 121 LATIN AMERICA: OTHER ALLERGEN DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 150
TABLE 122 MIDDLE EAST & AFRICA: OTHER ALLERGEN DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 150
9 ALLERGY DIAGNOSTICS MARKET, BY END USER 151
9.1 INTRODUCTION 152
TABLE 123 ALLERGY DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 152
9.2 HOSPITAL-BASED LABORATORIES & CLINICS 152
9.2.1 MORE ACCESSIBLE TO PATIENTS AND OFFER RAPID RESULTS 152
TABLE 124 ALLERGY DIAGNOSTICS MARKET FOR HOSPITAL-BASED LABORATORIES & CLINICS, BY REGION, 2022–2029 (USD MILLION) 153
TABLE 125 NORTH AMERICA: ALLERGY DIAGNOSTICS MARKET FOR HOSPITAL-BASED LABORATORIES & CLINICS, BY COUNTRY, 2022–2029 (USD MILLION) 153
TABLE 126 EUROPE: ALLERGY DIAGNOSTICS MARKET FOR HOSPITAL-BASED LABORATORIES & CLINICS, BY COUNTRY, 2022–2029 (USD MILLION) 154
TABLE 127 ASIA PACIFIC: ALLERGY DIAGNOSTICS MARKET FOR HOSPITAL-BASED LABORATORIES & CLINICS, BY COUNTRY, 2022–2029 (USD MILLION) 154
TABLE 128 LATIN AMERICA: ALLERGY DIAGNOSTICS MARKET FOR HOSPITAL-BASED LABORATORIES & CLINICS, BY COUNTRY, 2022–2029 (USD MILLION) 155
TABLE 129 MIDDLE EAST & AFRICA: ALLERGY DIAGNOSTICS MARKET FOR HOSPITAL-BASED LABORATORIES & CLINICS, BY COUNTRY, 2022–2029 (USD MILLION) 155
9.3 DIAGNOSTIC LABORATORIES 155
9.3.1 MAJOR END USERS OF ALLERGY DIAGNOSTIC PRODUCTS 155
TABLE 130 ALLERGY DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2022–2029 (USD MILLION) 156
TABLE 131 NORTH AMERICA: ALLERGY DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION) 156
TABLE 132 EUROPE: ALLERGY DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION) 157
TABLE 133 ASIA PACIFIC: ALLERGY DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION) 157
TABLE 134 LATIN AMERICA: ALLERGY DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION) 158
TABLE 135 MIDDLE EAST & AFRICA: ALLERGY DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION) 158
9.4 ACADEMIC RESEARCH INSTITUTES 158
9.4.1 RISING NUMBER OF INSTITUTES OFFERING ALLERGY TESTING TRAINING TO SUPPORT MARKET GROWTH 158
TABLE 136 ALLERGY DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2022–2029 (USD MILLION) 159
TABLE 137 NORTH AMERICA: ALLERGY DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION) 160
TABLE 138 EUROPE: ALLERGY DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION) 160
TABLE 139 ASIA PACIFIC: ALLERGY DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION) 161
TABLE 140 LATIN AMERICA: ALLERGY DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION) 161
TABLE 141 MIDDLE EAST & AFRICA: ALLERGY DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION) 161
9.5 OTHER END USERS 162
TABLE 142 ALLERGY DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2022–2029 (USD MILLION) 162
TABLE 143 NORTH AMERICA: ALLERGY DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION) 162
TABLE 144 EUROPE: ALLERGY DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION) 163
TABLE 145 ASIA PACIFIC: ALLERGY DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION) 163
TABLE 146 LATIN AMERICA: ALLERGY DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION) 164
TABLE 147 MIDDLE EAST & AFRICA: ALLERGY DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION) 164
10 ALLERGY DIAGNOSTICS MARKET, BY REGION 165
10.1 INTRODUCTION 166
TABLE 148 ALLERGY DIAGNOSTICS MARKET, BY REGION, 2022–2029 (USD MILLION) 166
10.2 NORTH AMERICA 166
10.2.1 NORTH AMERICA: RECESSION IMPACT 166
FIGURE 36 NORTH AMERICA: ALLERGY DIAGNOSTICS MARKET SNAPSHOT 167
TABLE 149 NORTH AMERICA: ALLERGY DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 168
TABLE 150 NORTH AMERICA: ALLERGY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 168
TABLE 151 NORTH AMERICA: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 168
TABLE 152 NORTH AMERICA: ALLERGY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 169
TABLE 153 NORTH AMERICA: ALLERGY DIAGNOSTICS MARKET FOR IN VIVO TESTS, BY TYPE, 2022–2029 (USD MILLION) 169
TABLE 154 NORTH AMERICA: ALLERGY DIAGNOSTICS MARKET, BY ALLERGEN, 2022–2029 (USD MILLION) 169
TABLE 155 NORTH AMERICA: ALLERGY DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 170
10.2.2 US 170
10.2.2.1 US to dominate North American allergy diagnostics market 170
TABLE 156 US: ALLERGY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 171
TABLE 157 US: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 171
TABLE 158 US: ALLERGY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 172
TABLE 159 US: ALLERGY DIAGNOSTICS MARKET FOR IN VIVO TESTS, BY TYPE, 2022–2029 (USD MILLION) 172
TABLE 160 US: ALLERGY DIAGNOSTICS MARKET, BY ALLERGEN, 2022–2029 (USD MILLION) 172
TABLE 161 US: ALLERGY DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 173
TABLE 162 US: ALLERGY DIAGNOSTICS MARKET, BY NUMBER OF PATIENTS BEING TESTED. 2018–2029 (MILLION) 173
10.2.3 CANADA 173
10.2.3.1 Rising funding activities in allergy diagnostics to drive market 173
TABLE 163 CANADA: ALLERGY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 174
TABLE 164 CANADA: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 174
TABLE 165 CANADA: ALLERGY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 175
TABLE 166 CANADA: ALLERGY DIAGNOSTICS MARKET FOR IN VIVO TESTS, BY TYPE, 2022–2029 (USD MILLION) 175
TABLE 167 CANADA: ALLERGY DIAGNOSTICS MARKET, BY ALLERGEN, 2022–2029 (USD MILLION) 175
TABLE 168 CANADA: ALLERGY DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 176
10.3 EUROPE 176
10.3.1 EUROPE: RECESSION IMPACT 176
TABLE 169 EUROPE: ALLERGY DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 177
TABLE 170 EUROPE: ALLERGY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 177
TABLE 171 EUROPE: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 178
TABLE 172 EUROPE: ALLERGY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 178
TABLE 173 EUROPE: ALLERGY DIAGNOSTICS MARKET FOR IN VIVO TESTS, BY TYPE, 2022–2029 (USD MILLION) 178
TABLE 174 EUROPE: ALLERGY DIAGNOSTICS MARKET, BY ALLERGEN, 2022–2029 (USD MILLION) 179
TABLE 175 EUROPE: ALLERGY DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 179
10.3.2 GERMANY 179
10.3.2.1 Germany to hold largest market share in Europe 179
TABLE 176 GERMANY: ALLERGY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 180
TABLE 177 GERMANY: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 180
TABLE 178 GERMANY: ALLERGY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 181
TABLE 179 GERMANY: ALLERGY DIAGNOSTICS MARKET FOR IN VIVO TESTS, BY TYPE, 2022–2029 (USD MILLION) 181
TABLE 180 GERMANY: ALLERGY DIAGNOSTICS MARKET, BY ALLERGEN, 2022–2029 (USD MILLION) 181
TABLE 181 GERMANY: ALLERGY DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 182
10.3.3 UK 182
10.3.3.1 Increasing prevalence of food anaphylaxis to support market growth 182
TABLE 182 UK: ALLERGY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 183
TABLE 183 UK: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 183
TABLE 184 UK: ALLERGY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 184
TABLE 185 UK: ALLERGY DIAGNOSTICS MARKET FOR IN VIVO TESTS, BY TYPE, 2022–2029 (USD MILLION) 184
TABLE 186 UK: ALLERGY DIAGNOSTICS MARKET, BY ALLERGEN, 2022–2029 (USD MILLION) 184
TABLE 187 UK: ALLERGY DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 185
10.3.4 FRANCE 185
10.3.4.1 Increasing reimbursements for allergy testing to support market growth 185
TABLE 188 FRANCE: ALLERGY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 186
TABLE 189 FRANCE: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 186
TABLE 190 FRANCE: ALLERGY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 186
TABLE 191 FRANCE: ALLERGY DIAGNOSTICS MARKET FOR IN VIVO TESTS, BY TYPE, 2022–2029 (USD MILLION) 187
TABLE 192 FRANCE: ALLERGY DIAGNOSTICS MARKET, BY ALLERGEN, 2022–2029 (USD MILLION) 187
TABLE 193 FRANCE: ALLERGY DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 187
10.3.5 ITALY 188
10.3.5.1 Presence of allergy diagnostic organizations to support research & demand for products 188
TABLE 194 ITALY: ALLERGY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 188
TABLE 195 ITALY: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 189
TABLE 196 ITALY: ALLERGY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 189
TABLE 197 ITALY: ALLERGY DIAGNOSTICS MARKET FOR IN VIVO TESTS, BY TYPE, 2022–2029 (USD MILLION) 189
TABLE 198 ITALY: ALLERGY DIAGNOSTICS MARKET, BY ALLERGEN, 2022–2029 (USD MILLION) 190
TABLE 199 ITALY: ALLERGY DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 190
10.3.6 SPAIN 190
10.3.6.1 Government initiatives and healthcare infrastructural development to drive market 190
TABLE 200 SPAIN: ALLERGY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 191
TABLE 201 SPAIN: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 191
TABLE 202 SPAIN: ALLERGY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 192
TABLE 203 SPAIN: ALLERGY DIAGNOSTICS MARKET FOR IN VIVO TESTS, BY TYPE, 2022–2029 (USD MILLION) 192
TABLE 204 SPAIN: ALLERGY DIAGNOSTICS MARKET, BY ALLERGEN, 2022–2029 (USD MILLION) 192
TABLE 205 SPAIN: ALLERGY DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 193
10.3.7 REST OF EUROPE 193
TABLE 206 REST OF EUROPE: ALLERGY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 194
TABLE 207 REST OF EUROPE: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 194
TABLE 208 REST OF EUROPE: ALLERGY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 194
TABLE 209 REST OF EUROPE: ALLERGY DIAGNOSTICS MARKET FOR IN VIVO TESTS, BY TYPE, 2022–2029 (USD MILLION) 195
TABLE 210 REST OF EUROPE: ALLERGY DIAGNOSTICS MARKET, BY ALLERGEN, 2022–2029 (USD MILLION) 195
TABLE 211 REST OF EUROPE: ALLERGY DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 196
10.4 ASIA PACIFIC 196
10.4.1 ASIA PACIFIC: RECESSION IMPACT 196
FIGURE 37 ASIA PACIFIC: ALLERGY DIAGNOSTICS MARKET SNAPSHOT 197
TABLE 212 ASIA PACIFIC: ALLERGY DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 198
TABLE 213 ASIA PACIFIC: ALLERGY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 198
TABLE 214 ASIA PACIFIC: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 198
TABLE 215 ASIA PACIFIC: ALLERGY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 199
TABLE 216 ASIA PACIFIC: ALLERGY DIAGNOSTICS MARKET FOR IN VIVO TESTS, BY TYPE, 2022–2029 (USD MILLION) 199
TABLE 217 ASIA PACIFIC: ALLERGY DIAGNOSTICS MARKET, BY ALLERGEN, 2022–2029 (USD MILLION) 199
TABLE 218 ASIA PACIFIC: ALLERGY DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 200
10.4.2 CHINA 200
10.4.2.1 China to hold largest market share in APAC 200
TABLE 219 CHINA: ALLERGY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 201
TABLE 220 CHINA: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 201
TABLE 221 CHINA: ALLERGY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 201
TABLE 222 CHINA: ALLERGY DIAGNOSTICS MARKET FOR IN VIVO TESTS, BY TYPE, 2022–2029 (USD MILLION) 202
TABLE 223 CHINA: ALLERGY DIAGNOSTICS MARKET, BY ALLERGEN, 2022–2029 (USD MILLION) 202
TABLE 224 CHINA: ALLERGY DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 202
10.4.3 JAPAN 203
10.4.3.1 Increasing prevalence of allergies among children to propel demand for allergy diagnostics 203
TABLE 225 JAPAN: ALLERGY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 203
TABLE 226 JAPAN: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 204
TABLE 227 JAPAN: ALLERGY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 204
TABLE 228 JAPAN: ALLERGY DIAGNOSTICS MARKET FOR IN VIVO TESTS, BY TYPE, 2022–2029 (USD MILLION) 204
TABLE 229 JAPAN: ALLERGY DIAGNOSTICS MARKET, BY ALLERGEN, 2022–2029 (USD MILLION) 205
TABLE 230 JAPAN: ALLERGY DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 205
10.4.4 INDIA 205
10.4.4.1 Limited awareness regarding allergy management to limit market growth 205
TABLE 231 INDIA: ALLERGY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 206
TABLE 232 INDIA: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 207
TABLE 233 INDIA: ALLERGY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 207
TABLE 234 INDIA: ALLERGY DIAGNOSTICS MARKET FOR IN VIVO TESTS, BY TYPE, 2022–2029 (USD MILLION) 207
TABLE 235 INDIA: ALLERGY DIAGNOSTICS MARKET, BY ALLERGEN, 2022–2029 (USD MILLION) 208
TABLE 236 INDIA: ALLERGY DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 208
10.4.5 AUSTRALIA 208
10.4.5.1 High prevalence of food allergies to drive market 208
TABLE 237 AUSTRALIA: ALLERGY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 209
TABLE 238 AUSTRALIA: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 209
TABLE 239 AUSTRALIA: ALLERGY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 210
TABLE 240 AUSTRALIA: ALLERGY DIAGNOSTICS MARKET FOR IN VIVO TESTS, BY TYPE, 2022–2029 (USD MILLION) 210
TABLE 241 AUSTRALIA: ALLERGY DIAGNOSTICS MARKET, BY ALLERGEN, 2022–2029 (USD MILLION) 210
TABLE 242 AUSTRALIA: ALLERGY DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 211
10.4.6 REST OF ASIA PACIFIC 211
TABLE 243 REST OF ASIA PACIFIC: ALLERGY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 212
TABLE 244 REST OF ASIA PACIFIC: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 212
TABLE 245 REST OF ASIA PACIFIC: ALLERGY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 212
TABLE 246 REST OF ASIA PACIFIC: ALLERGY DIAGNOSTICS MARKET FOR IN VIVO TESTS, BY TYPE, 2022–2029 (USD MILLION) 213
TABLE 247 REST OF ASIA PACIFIC: ALLERGY DIAGNOSTICS MARKET, BY ALLERGEN, 2022–2029 (USD MILLION) 213
TABLE 248 REST OF ASIA PACIFIC: ALLERGY DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 213
10.5 LATIN AMERICA 214
10.5.1 LATIN AMERICA: RECESSION IMPACT 214
TABLE 249 LATIN AMERICA: ALLERGY DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 214
TABLE 250 LATIN AMERICA: ALLERGY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 214
TABLE 251 LATIN AMERICA: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 215
TABLE 252 LATIN AMERICA: ALLERGY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 215
TABLE 253 LATIN AMERICA: ALLERGY DIAGNOSTICS MARKET FOR IN VIVO TESTS, BY TYPE, 2022–2029 (USD MILLION) 215
TABLE 254 LATIN AMERICA: ALLERGY DIAGNOSTICS MARKET, BY ALLERGEN, 2022–2029 (USD MILLION) 216
TABLE 255 LATIN AMERICA: ALLERGY DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 216
10.5.2 BRAZIL 216
10.5.2.1 Brazil to hold largest market share in Latin America 216
TABLE 256 BRAZIL: ALLERGY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 217
TABLE 257 BRAZIL: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 217
TABLE 258 BRAZIL: ALLERGY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 217
TABLE 259 BRAZIL: ALLERGY DIAGNOSTICS MARKET FOR IN VIVO TESTS, BY TYPE, 2022–2029 (USD MILLION) 218
TABLE 260 BRAZIL: ALLERGY DIAGNOSTICS MARKET, BY ALLERGEN, 2022–2029 (USD MILLION) 218
TABLE 261 BRAZIL: ALLERGY DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 218
10.5.3 MEXICO 219
10.5.3.1 Growing focus on awareness training programs to boost demand 219
TABLE 262 MEXICO: ALLERGY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 219
TABLE 263 MEXICO: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 220
TABLE 264 MEXICO: ALLERGY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 220
TABLE 265 MEXICO: ALLERGY DIAGNOSTICS MARKET FOR IN VIVO TESTS, BY TYPE, 2022–2029 (USD MILLION) 220
TABLE 266 MEXICO: ALLERGY DIAGNOSTICS MARKET, BY ALLERGEN, 2022–2029 (USD MILLION) 221
TABLE 267 MEXICO: ALLERGY DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 221
10.5.4 REST OF LATIN AMERICA 221
TABLE 268 REST OF LATIN AMERICA: ALLERGY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 222
TABLE 269 REST OF LATIN AMERICA: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 222
TABLE 270 REST OF LATIN AMERICA: ALLERGY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 223
TABLE 271 REST OF LATIN AMERICA: ALLERGY DIAGNOSTICS MARKET FOR IN VIVO TESTS, BY TYPE, 2022–2029 (USD MILLION) 223
TABLE 272 REST OF LATIN AMERICA: ALLERGY DIAGNOSTICS MARKET, BY ALLERGEN, 2022–2029 (USD MILLION) 223
TABLE 273 REST OF LATIN AMERICA: ALLERGY DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 224
10.6 MIDDLE EAST & AFRICA 224
10.6.1 MIDDLE EAST & AFRICA: RECESSION IMPACT 224
TABLE 274 MIDDLE EAST & AFRICA: ALLERGY DIAGNOSTICS MARKET, BY REGION, 2022–2029 (USD MILLION) 224
TABLE 275 MIDDLE EAST & AFRICA: ALLERGY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 225
TABLE 276 MIDDLE EAST & AFRICA: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 225
TABLE 277 MIDDLE EAST & AFRICA: ALLERGY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 225
TABLE 278 MIDDLE EAST & AFRICA: ALLERGY DIAGNOSTICS MARKET FOR IN VIVO TESTS, BY TYPE, 2022–2029 (USD MILLION) 226
TABLE 279 MIDDLE EAST & AFRICA: ALLERGY DIAGNOSTICS MARKET, BY ALLERGEN, 2022–2029 (USD MILLION) 226
TABLE 280 MIDDLE EAST & AFRICA: ALLERGY DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 226
10.6.2 GCC COUNTRIES 227
10.6.2.1 Rising healthcare spending to drive market 227
TABLE 281 GCC COUNTRIES: ALLERGY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 228
TABLE 282 GCC COUNTRIES: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 228
TABLE 283 GCC COUNTRIES: ALLERGY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 228
TABLE 284 GCC COUNTRIES: ALLERGY DIAGNOSTICS MARKET FOR IN VIVO TESTS, BY TYPE, 2022–2029 (USD MILLION) 229
TABLE 285 GCC COUNTRIES: ALLERGY DIAGNOSTICS MARKET, BY ALLERGEN, 2022–2029 (USD MILLION) 229
TABLE 286 GCC COUNTRIES: ALLERGY DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 229
10.6.3 REST OF MIDDLE EAST & AFRICA 230
TABLE 287 REST OF MIDDLE EAST & AFRICA: ALLERGY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 230
TABLE 288 REST OF MIDDLE EAST & AFRICA: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 230
TABLE 289 REST OF MIDDLE EAST & AFRICA: ALLERGY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 231
TABLE 290 REST OF MIDDLE EAST & AFRICA: ALLERGY DIAGNOSTICS MARKET FOR IN VIVO TESTS, BY TYPE, 2022–2029 (USD MILLION) 231
TABLE 291 REST OF MIDDLE EAST & AFRICA: ALLERGY DIAGNOSTICS MARKET, BY ALLERGEN, 2022–2029 (USD MILLION) 231
TABLE 292 REST OF MIDDLE EAST & AFRICA: ALLERGY DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 232
11 COMPETITIVE LANDSCAPE 233
11.1 OVERVIEW 233
11.2 STRATEGIES ADOPTED BY KEY PLAYERS 233
TABLE 293 OVERVIEW OF STRATEGIES DEPLOYED BY KEY ALLERGY DIAGNOSTICS COMPANIES 233
11.3 REVENUE ANALYSIS 235
FIGURE 38 REVENUE ANALYSIS FOR KEY COMPANIES IN ALLERGY DIAGNOSTICS MARKET, 2019–2023 (USD MILLION) 235
11.4 MARKET SHARE ANALYSIS 236
FIGURE 39 ALLERGY DIAGNOSTICS MARKET SHARE ANALYSIS, BY KEY PLAYER (2023) 236
TABLE 294 ALLERGY DIAGNOSTICS MARKET: DEGREE OF COMPETITION 236
11.5 BRAND/PRODUCT COMPARISON 238
FIGURE 40 ALLERGY DIAGNOSTICS MARKET: BRAND COMPARISON FOR IMMUNOASSAY ANALYZERS, BY KEY PLAYER 238
11.6 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 238
11.6.1 STARS 239
11.6.2 EMERGING LEADERS 239
11.6.3 PERVASIVE PLAYERS 239
11.6.4 PARTICIPANTS 239
FIGURE 41 ALLERGY DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023 240
11.6.5 COMPANY FOOTPRINT ANALYSIS 241
FIGURE 42 ALLERGY DIAGNOSTICS MARKET: COMPANY FOOTPRINT 241
TABLE 295 ALLERGY DIAGNOSTICS MARKET: PRODUCT & SERVICE FOOTPRINT 241
TABLE 296 ALLERGY DIAGNOSTICS MARKET: REGIONAL FOOTPRINT 242
TABLE 297 ALLERGY DIAGNOSTICS MARKET: TEST TYPE FOOTPRINT 243
TABLE 298 ALLERGY DIAGNOSTICS MARKET: ALLERGENS FOOTPRINT 243
11.7 COMPETITIVE EVALUATION MATRIX: STARTUPS/SMES, 2023 244
11.7.1 PROGRESSIVE COMPANIES 244
11.7.2 RESPONSIVE COMPANIES 244
11.7.3 DYNAMIC COMPANIES 244
11.7.4 STARTING BLOCKS 244
FIGURE 43 ALLERGY DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 245
11.7.5 COMPETITIVE BENCHMARKING 246
TABLE 299 ALLERGY DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 246
TABLE 300 PRODUCT & SERVICE FOOTPRINT (STARTUPS/SMES) 246
TABLE 301 REGIONAL FOOTPRINT (STARTUPS/SMES) 247
TABLE 302 COMPANY FOOTPRINT (STARTUPS/SMES) 247
11.8 VALUATION AND FINANCIAL METRICS OF ALLERGY DIAGNOSTICS VENDORS 248
FIGURE 44 EV/EBITDA OF KEY VENDORS 248
FIGURE 45 EV/REV OF KEY VENDORS 248
FIGURE 46 BETA (5 YEARS) OF KEY VENDORS 249
FIGURE 47 1 YEAR PRICE TOTAL RETURN OF KEY VENDORS 249
11.9 COMPETITIVE SCENARIO 250
11.9.1 PRODUCT LAUNCHES & APPROVALS 250
TABLE 303 ALLERGY DIAGNOSTICS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2020–MARCH 2024 250
11.9.2 DEALS 250
TABLE 304 ALLERGY DIAGNOSTICS MARKET: DEALS, JANUARY 2020–MARCH 2024 250
11.9.3 EXPANSIONS 251
TABLE 305 ALLERGY DIAGNOSTICS MARKET: EXPANSIONS, JANUARY 2020–MARCH 2024 251
12 COMPANY PROFILES 252
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1 KEY PLAYERS 252
12.1.1 DANAHER CORPORATION 252
TABLE 306 DANAHER CORPORATION: COMPANY OVERVIEW 252
FIGURE 48 DANAHER CORPORATION: COMPANY SNAPSHOT (2023) 253
TABLE 307 DANAHER CORPORATION: PRODUCTS OFFERED 253
12.1.2 THERMO FISHER SCIENTIFIC INC. 255
TABLE 308 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 255
FIGURE 49 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023) 256
TABLE 309 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 256
TABLE 310 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES & APPROVALS 257
TABLE 311 THERMO FISHER SCIENTIFIC INC.: DEALS 257
12.1.3 CANON, INC. (MINARIS MEDICAL AMERICA, INC.) 259
TABLE 312 CANON, INC. (MINARIS MEDICAL AMERICA, INC.): COMPANY OVERVIEW 259
FIGURE 50 CANON, INC. (MINARIS MEDICAL AMERICA, INC.): COMPANY SNAPSHOT (2023) 260
TABLE 313 CANON, INC. (MINARIS MEDICAL AMERICA, INC.): PRODUCTS OFFERED 261
TABLE 314 CANON, INC. (MINARIS MEDICAL AMERICA, INC.): DEALS 261
12.1.4 SIEMENS HEALTHINEERS AG 263
TABLE 315 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 263
FIGURE 51 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2023) 264
TABLE 316 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED 265
12.1.5 EUROFINS SCIENTIFIC 266
TABLE 317 EUROFINS SCIENTIFIC: COMPANY OVERVIEW 266
FIGURE 52 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2023) 267
TABLE 318 EUROFINS SCIENTIFIC: PRODUCTS OFFERED 268
TABLE 319 EUROFINS SCIENTIFIC: EXPANSIONS 268
12.1.6 REVVITY, INC. (EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG) 269
TABLE 320 REVVITY, INC. (EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG): COMPANY OVERVIEW 269
FIGURE 53 REVVITY, INC. (EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG): COMPANY SNAPSHOT (2023) 270
TABLE 321 REVVITY, INC. (EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG): PRODUCTS OFFERED 271
TABLE 322 REVVITY, INC. (EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG): DEALS 271
12.1.7 BIOMÉRIEUX SA 272
TABLE 323 BIOMÉRIEUX SA: COMPANY OVERVIEW 272
FIGURE 54 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2022) 273
TABLE 324 BIOMÉRIEUX SA: PRODUCTS OFFERED 274
12.1.8 STALLERGENES GREER LTD. 275
TABLE 325 STALLERGENES GREER LTD.: COMPANY OVERVIEW 275
TABLE 326 STALLERGENES GREER LTD.: PRODUCTS OFFERED 275
TABLE 327 STALLERGENES GREER LTD.: DEALS 275
12.1.9 ROMER LABS DIVISION HOLDING GMBH 276
TABLE 328 ROMER LABS DIVISION HOLDING GMBH: COMPANY OVERVIEW 276
FIGURE 55 ROMER LABS DIVISION HOLDING GMBH: COMPANY SNAPSHOT (2022) 277
TABLE 329 ROMER LABS DIVISION HOLDING GMBH: PRODUCTS OFFERED 277
TABLE 330 ROMER LABS DIVISION HOLDING GMBH: DEALS 278
12.1.10 HOLLISTERSTIER ALLERGY 279
TABLE 331 HOLLISTERSTIER ALLERGY: COMPANY OVERVIEW 279
FIGURE 56 JUBILANT PHARMA LIMITED: COMPANY SNAPSHOT (2022) 280
TABLE 332 HOLLISTERSTIER ALLERGY: PRODUCTS OFFERED 281
12.1.11 OMEGA DIAGNOSTICS GROUP PLC 282
TABLE 333 OMEGA DIAGNOSTICS GROUP PLC: COMPANY OVERVIEW 282
FIGURE 57 OMEGA DIAGNOSTICS GROUP PLC: COMPANY SNAPSHOT (2023) 283
TABLE 334 OMEGA DIAGNOSTICS GROUP PLC: PRODUCTS OFFERED 284
12.2 OTHER PLAYERS 285
12.2.1 HOB BIOTECH GROUP CORP., LTD. 285
TABLE 335 HOB BIOTECH GROUP CORP., LTD.: COMPANY OVERVIEW 285
12.2.2 HYCOR BIOMEDICAL 286
TABLE 336 HYCOR BIOMEDICAL: COMPANY OVERVIEW 286
12.2.3 LINCOLN DIAGNOSTICS, INC. 287
TABLE 337 LINCOLN DIAGNOSTICS, INC.: COMPANY OVERVIEW 287
12.2.4 R-BIOPHARM AG 288
TABLE 338 R-BIOPHARM AG: COMPANY OVERVIEW 288
12.2.5 ASTRA BIOTECH GMBH 289
TABLE 339 ASTRA BIOTECH GMBH: COMPANY OVERVIEW 289
12.2.6 ERBA GROUP 290
TABLE 340 ERBA GROUP: COMPANY OVERVIEW 290
12.2.7 AESKU.GROUP GMBH 291
TABLE 341 AESKU.GROUP GMBH: COMPANY OVERVIEW 291
12.2.8 ACON LABORATORIES, INC. 292
TABLE 342 ACON LABORATORIES, INC.: COMPANY OVERVIEW 292
12.2.9 ALCIT INDIA PVT. LTD. 293
TABLE 343 ALCIT INDIA PVT. LTD.: COMPANY OVERVIEW 293
12.2.10 BIOPANDA REAGENTS LTD. 294
TABLE 344 BIOPANDA REAGENTS LTD.: COMPANY OVERVIEW 294
12.2.11 BIOSIDE S.R.L. 295
TABLE 345 BIOSIDE S.R.L.: COMPANY OVERVIEW 295
12.2.12 CREATIVE DIAGNOSTIC MEDICARE PVT. LTD. 296
TABLE 346 CREATIVE DIAGNOSTIC MEDICARE PVT. LTD.: COMPANY OVERVIEW 296
12.2.13 DST DIAGNOSTISCHE SYSTEME & TECHNOLOGIEN GMBH 297
TABLE 347 DST DIAGNOSTISCHE SYSTEME & TECHNOLOGIEN GMBH: COMPANY OVERVIEW 297
12.2.14 DR. FOOKE LABORATORIEN GMBH 298
TABLE 348 DR. FOOKE LABORATORIEN GMBH: COMPANY OVERVIEW 298
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX 299
13.1 DISCUSSION GUIDE 299
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 304
13.3 CUSTOMIZATION OPTIONS 306
13.4 RELATED REPORTS 306
13.5 AUTHOR DETAILS 307